Articles
Redefining the Blockbuster Model: Why the $1 billion entry point is no longer sufficient - part 2

Redefining the Blockbuster Model: Why the $1 billion entry ...

Sarah Rickwood concludes her two-part article in which she questions how we can truly define a ‘Blockbuster drugs’. An effective approach is defining blockbuster products in terms of a fixed share of the value of the global pharmaceutical market...

Articles
Patient perspectives: Tiffany Peterson

Patient perspectives: Tiffany Peterson

Tiffany Peterson (also known as Tiffany and Lupus) shares what it is like to be a patient with Lupus and how pharma can better work with patients such as her. Frustrated with the lack of information she received after receiving her diagnosis of Lupus, Tiffany Peterson didn’t want other patients to…

Articles
Perspectives on CME: part 4 – the impact of technology on CME

Perspectives on CME: part 4 – the impact of technology on CM...

In the fourth part of our interview series with Lawrence Sherman we learn how technology has shaped CME and where Lawrence gets his inspiration from in his work. In this interview series with CME expert Lawrence Sherman we’ve learned how CME can be of real value to the learner, in addition to...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. ESMO26: Tango sees 82% ORR with combo in pancreatic cancer
  2. Roche offers $15bn for strategic-level deal with Hansoh
  3. ESMO26: Moderna, MSD reveal cancer jab data early after leak
  4. Clinical trial setup times fall sharply in UK
  5. Despite US policy changes, drug prices stay stubbornly high

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more